CoChat

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Open access
Retseck, Janet, Nasr, Alexis, Lin, Yan, Lin, Huang, Mendiratta, Prateek, Butterfield, Lisa H., Tarhini, Ahmad A. · 2018 · Journal of Translational Medicine

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We previously reported early on-treatment significant modulation in circulating regulatory T cell (Treg), myeloid derived suppressor cells (MDSC) and antigen-specific type I CD4+ and CD8+ T cells that correlated with clinical outcome in regionally advanced melanoma patients treated with neoadjuvant ipilimumab. Here, we investigated the long term immunologic impact of CTLA4 blockade. METHODS: Patients were treated with ipilimumab given at 10 mg/kg IV every 3 weeks for 2 doses bracketing surgery. Blood specimens were collected at baseline and during treatment for up to 9 months. We tested immune responses at 3, 6, and 9 months utilizing multicolor flow cytometry. We compared frequencies of circulating Treg and MDSC on-study to baseline levels, as well as frequencies of CD4+ and CD8+ T cells specific to shared tumor-associated antigens (Gp-100, MART-1, NY-ESO-1). RESULTS: Levels of Treg significantly increased when measured at 6 weeks following ipilimumab but returned to baseline by 3 months, with no significant difference in Treg levels between relapsed and relapse-free groups at 3, 6 or 9 months. However, lower baseline levels of circulating Treg (CD4+CD25hi+CD39+) were significantly associated with better relapse free survival (RFS) (p = 0.04). Levels of circulating monocytic HLA-DR+/loCD14+ MDSC were lower at baseline in the relapse-free group and further decreased at 6 weeks, though the differences did not reach statistical significance including measurements at 3, 6 or 9 months. We detected evidence of type I (interferon-γ producing), activated (CD69+) CD4+ and CD8+ antigen-specific T cell immunity against cancer-testis (NY-ESO-1) as well as melanocytic lineage (MART-1, gp100) antigens in the absence of therapeutic vaccination. These responses were significantly boosted at 6 weeks and persisted at 3, 6 and 9 months following the initiation of ipilimumab. CONCLUSIONS: Lower Treg levels at baseline are significantly associated with RFS and increased Treg frequency after CTLA4 blockade was only transient. Lower MDSC was also associated with RFS and MDSC levels were further decreased after ipilimumab. Tumor specific effector immune responses are boosted with CTLA4 blockade and tend to be durable. Trial registration ClinicalTrials.gov Identifier: NCT00972933.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-018-1563-y

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Neoadjuvant ipilimumab study design. Patients with locally and/or regionally advanced melanoma were enrolled and underwent excisional biopsy. They then received 2 cycles of ipilimumab 10 mg/kg every 21 days. A radical definitive surgery was then performed. Patients received 2 additional cycles of ipi 10 mg/kg every 21 days. Blood specimens (serum/peripheral blood monitoring) were collected at baseline, 6 weeks, 3, 6, and 9 months
Fig. 1 Neoadjuvant ipilimumab study design. Patients with locally and/or regionally advanced melanoma were enrolled and underwent excisional biopsy. They then received 2 cycles of ipilimumab 10 mg/kg every 21 days. A radical definitive surgery was then performed. Patients received 2 additional cycles of ipi 10 mg/kg every 21 days. Blood specimens (serum/peripheral blood monitoring) were collected at baseline, 6 weeks, 3, 6, and 9 monthsCC BY · PubMed Central
Fig. 2 Frequencies of peripheral blood CD4+CD25hi+CD39+ Treg at baseline and 3 months in patients who relapsed or were relapse-free at 9 months. a There was a significant difference in the percent of CD4+CD25hiCD39+ Treg at baseline between patients who had not relapsed at 9 months versus those who relapsed or died (p = 0.04). Those in the relapse group had significantly higher Treg levels. b By month 3, Treg in both groups tended to be higher compared to baseline, but to a greater degree in the relapse-free group. There was no significant difference in Treg levels at month 3 between the two groups (p = 0.266). Y axis shows the % of CD4+CD25hi+ cells that express CD39
Fig. 2 Frequencies of peripheral blood CD4+CD25hi+CD39+ Treg at baseline and 3 months in patients who relapsed or were relapse-free at 9 months. a There was a significant difference in the percent of CD4+CD25hiCD39+ Treg at baseline between patients who had not relapsed at 9 months versus those who relapsed or died (p = 0.04). Those in the relapse group had significantly higher Treg levels. b By month 3, Treg in both groups tended to be higher compared to baseline, but to a greater degree in the relapse-free group. There was no significant difference in Treg levels at month 3 between the two groups (p = 0.266). Y axis shows the % of CD4+CD25hi+ cells that express CD39CC BY · PubMed Central
Fig. 3 Frequencies of CD4+CD25hiCD39+ Treg at baseline in healthy donors and patients. a Median levels of CD39+ Treg at baseline was lower in patients than in healthy donors, but the difference did not reach statistical significance (p = 0.144). b Median levels of CD39+ Treg at baseline was highest in healthy donors and lowest in non-relapsed patients, but the difference was not significant
Fig. 3 Frequencies of CD4+CD25hiCD39+ Treg at baseline in healthy donors and patients. a Median levels of CD39+ Treg at baseline was lower in patients than in healthy donors, but the difference did not reach statistical significance (p = 0.144). b Median levels of CD39+ Treg at baseline was highest in healthy donors and lowest in non-relapsed patients, but the difference was not significantCC BY · PubMed Central
Fig. 4 Frequencies of CD4+CD25hiFoxp3+ Treg and CD4+CD25hiCD39+ Treg from baseline through 9 months in patients who did not relapse or relapsed at 9 months. The solid blue line represents the median value of Treg for the relapse-free group, and the solid red line represents the median value for the relapsed group. a The levels of CD4+CD25hiFoxp3+ Treg increased at 6 weeks in both groups but returned to almost baseline levels starting 3 months. There were no significant differences in CD4+CD25hiFoxp3+ Treg between the two groups at baseline, 3, 6, or 9 months. b At 3 months, levels of CD4+CD25hiCD39+ Treg returned nearly to baseline. There were no significant differences in Treg levels between the two groups starting at 3 months
Fig. 4 Frequencies of CD4+CD25hiFoxp3+ Treg and CD4+CD25hiCD39+ Treg from baseline through 9 months in patients who did not relapse or relapsed at 9 months. The solid blue line represents the median value of Treg for the relapse-free group, and the solid red line represents the median value for the relapsed group. a The levels of CD4+CD25hiFoxp3+ Treg increased at 6 weeks in both groups but returned to almost baseline levels starting 3 months. There were no significant differences in CD4+CD25hiFoxp3+ Treg between the two groups at baseline, 3, 6, or 9 months. b At 3 months, levels of CD4+CD25hiCD39+ Treg returned nearly to baseline. There were no significant differences in Treg levels between the two groups starting at 3 monthsCC BY · PubMed Central
Fig. 5 Frequencies of circulating HLA-DR+lowCD14+ MDSC at baseline and 3 months. a Levels of circulating monocytic HLA-DR+lowCD14+ MDSC were lower at baseline in the relapse-free group. b Median levels increased in the non-relapsed groups at 3 months while staying the same in the relapsed group, but there were no significant differences in levels of MDSC at 3, 6, or 9 months between the 2 groups
Fig. 5 Frequencies of circulating HLA-DR+lowCD14+ MDSC at baseline and 3 months. a Levels of circulating monocytic HLA-DR+lowCD14+ MDSC were lower at baseline in the relapse-free group. b Median levels increased in the non-relapsed groups at 3 months while staying the same in the relapsed group, but there were no significant differences in levels of MDSC at 3, 6, or 9 months between the 2 groupsCC BY · PubMed Central
Fig. 6 Forest Plots of Type I CD4 and CD8 Ag-specific T Cell Immunity (N = 27) at 6 weeks and at 3 months. Evidence of type I CD4+ and CD8+ antigen-specific T cell immunity against shared melanoma antigens, including lineage antigens (MART-1, gp-100) and cancer testis antigen (NY-ESO1), in the absence of prior vaccination. These responses were boosted after ipilimumab at a 6 weeks and b 3 months
Fig. 6 Forest Plots of Type I CD4 and CD8 Ag-specific T Cell Immunity (N = 27) at 6 weeks and at 3 months. Evidence of type I CD4+ and CD8+ antigen-specific T cell immunity against shared melanoma antigens, including lineage antigens (MART-1, gp-100) and cancer testis antigen (NY-ESO1), in the absence of prior vaccination. These responses were boosted after ipilimumab at a 6 weeks and b 3 monthsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. Nishikawa H Sakaguchi S Regulatory T cells in cancer immunotherapy Cur Opin Immunol 2014 27 1 7 10.1016/j.coi.2013.12.005 24413387 · DOI · Paper page

Cited by

See all 53

Metadata

Authors
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A.
Affiliations
  • UPMC Hillman Cancer Center (US)
  • Cleveland Clinic (US)
  • University of Pittsburgh (US)
Corresponding author
Tarhini, Ahmad A.
Venue
Journal of Translational Medicine
Published
2018-07-04
Volume
16
Issue
1
Pages
184-184
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2810002197
Cited by
51
References
54
Citations by year
2026: 2 · 2025: 7 · 2024: 8 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 9 · 2019: 4
FWCI
1.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Foundation for the National Institutes of Health (P50 CA121973, P30 CA047904)
  • Bristol-Myers Squibb (CA184-082)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
CTLA-4 blockade, ipilimumab, melanoma, regulatory T cells, myeloid-derived suppressor cells, tumor-infiltrating lymphocytes, antigen-specific T cells, NY-ESO-1, Melan-A, gp100, cancer-testis antigens, interferon-gamma, CD69, relapse-free survival, neoadjuvant immunotherapy
MeSH terms
Ipilimumab, Adult, Aged, Aged, 80 and over, Female, Humans, Immunity, Immunotherapy, Male, Melanoma, Middle Aged, Time Factors, Neoadjuvant Therapy, T-Lymphocytes, Regulatory, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. https://app.cochat.ai/papers/10.1186/s12967-018-1563-y
The paper
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018). Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. Journal of Translational Medicine. https://doi.org/10.1186/s12967-018-1563-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.